Biology Faculty Articles

Title

Effects of Plasma HIV RNA, CD4+ T Lymphocytes, and the Chemokine Receptors CCR5 and CCR2b on HIV Disease Progression in Hemophiliacs

Document Type

Article

Publication Date

8-1-1999

Publication Title

Journal of Acquired Immune Deficiency Syndromes

Keywords

Genetic resistance, Host factors, Markers, Viral load, Chemokine receptors

ISSN

1525-4135

Volume

21

Issue/No.

4

First Page

317

Last Page

325

Abstract

We have investigated the effects of plasma HIV RNA, CD4+ T lymphocytes and chemokine receptors CCR5 and CCR2b on HIV disease progression in hemophiliacs. We prospectively observed during follow-up 207 HIV-infected hemophiliacs in the Hemophilia Growth and Development Study. Plasma HIV RNA was measured on cryopreserved plasma from enrollment using the Chiron Corporation bDNA (version 2.0) assay. Genotype variants CCR2b-641 and CCR5-Δ32 were detected using standard molecular techniques. Those with the mutant allele for CCR2b, and to a lesser extent CCR5, had lower plasma HIV RNA, and higher CD4+ T lymphocytes than did those without these genetic variants. After controlling for the effects of plasma HIV RNA and CD4+ T lymphocytes, those with the CCR2b mutant allele compared with those wild-type, had a trend toward a lower risk of progression to AIDS, adjusted relative hazard of 1.94 (95% confidence interval [CI], 0.9-4.18; p = .092), and AIDS-related death, relative hazard 1.97 (95% CI, 0.98-4.00; p = .059). We conclude that plasma HIV RNA, CD4+ T lymphocytes, and CCR genotypes are correlated, and the protective affect of CCR2b against HIV disease progression is not completely explained by plasma HIV RNA or CD4+ T-lymphocyte number.

Comments

©1999 Lippincott Williams & Wilkins, Inc., Philadelphia

Additional Comments

Bureau of Maternal and Child Health and Resources Department grant #: MCJ-060570 (formerly National Institute of Child Health and Human Development NO1-HD-4-3200); National Center for Research Resources grant #s: MO1-RR06020, MO1-RR00059, (M)1-RR02558; National Cancer Institute contract #: NO11-CO-56000

ORCID ID

0000-0001-7353-8301

ResearcherID

N-1726-2015

This document is currently not available here.

Find in your library

Share

COinS